Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.

Commercially available doxorubicin-loaded long-circulating liposomes (Doxil, Alza Pharmaceuticals) were modified with the monoclonal nucleosome (NS)-specific 2C5 antibody (mAb 2C5) that recognizes a broad variety of tumors via the tumor cell surface-bound NSs. For incorporation into liposomes, mAb 2C5 was modified with poly(ethylene glycol)-phosphatidyl ethanolamine conjugate (PEG-PE) with the free PEG terminus activated with the p-nitrophenylcarbonyl group (pNP-PEG-PE). Derivatives of mAb 2C5 containing a variable number of PEG-PE residues (10-32) per protein molecule were prepared with a reasonably good preservation of the antibody specific activity even at the highest degree of modification. PEG-PE-modified antibody quantitatively incorporated into the liposomal membrane of doxorubicin-loaded liposomes with a loss of not more than 20% of the encapsulated doxorubicin. 2C5-targeted Doxil liposomes acquired the ability to recognize NSs and specifically bind to various tumor cells. Doxorubicin-loaded long-circulating liposomes modified with the mAb 2C5 kill various tumor cells in vitro with the efficiency higher than non-targeted doxorubicin-loaded liposomes.

[1]  S. Takeoka,et al.  Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. , 2000, Bioconjugate chemistry.

[2]  Z. Amoura,et al.  Binding of nucleosomes to a cell surface receptor: Redistribution and endocytosis in the presence of lupus antibodies , 1996, European journal of immunology.

[3]  R. Gaspar,et al.  Use of the Post-Insertion Technique to Insert Peptide Ligands into Pre-Formed Stealth Liposomes with Retention of Binding Activity and Cytotoxicity , 2002, Pharmaceutical Research.

[4]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[5]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Gaspar,et al.  A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. , 2001, Biochimica et biophysica acta.

[7]  D. Bell,et al.  The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. , 1991, Clinical immunology and immunopathology.

[8]  V. Torchilin,et al.  Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. , 1995, Immunology letters.

[9]  J. Markovits,et al.  A monoclonal anti-double-stranded DNA autoantibody binds to a 94-kDa cell-surface protein on various cell types via nucleosomes or a DNA-histone complex. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  V. Torchilin,et al.  p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.

[11]  S. Kennedy,et al.  A fluorescence-based protein assay for use with a microplate reader. , 1993, Analytical biochemistry.

[12]  R. Haugland.  Coupling of monoclonal antibodies with fluorophores. , 1995, Methods in molecular biology.

[13]  V. Torchilin,et al.  Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens. , 1985, Analytical biochemistry.

[14]  E. Moase,et al.  Use of the post-insertion method for the formation of ligand-coupled liposomes. , 2002, Cellular & molecular biology letters.

[15]  Torchilin Vp,et al.  A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. , 1997, Oncology research.

[16]  G Blume,et al.  Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.

[17]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[18]  P. Low,et al.  Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. , 1995, Biochimica et biophysica acta.

[19]  K. Skubitz.  Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma* , 2003, Cancer investigation.

[20]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[21]  V. Torchilin,et al.  Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. , 1998, Cancer detection and prevention.

[22]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[23]  G Gregoriadis,et al.  Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.

[24]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[25]  V. Torchilin,et al.  Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .

[26]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[27]  D. Tzemach,et al.  Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.

[28]  Vladimir P. Torchilin,et al.  Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Tzemach,et al.  Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  T. Ishida,et al.  A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs , 1999, FEBS letters.

[31]  V. Torchilin,et al.  ATP-containing immunoliposomes specific for cardiac myosin. , 2004, Current drug delivery.

[32]  Ananth Annapragada,et al.  Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. , 2003, Journal of controlled release : official journal of the Controlled Release Society.